Alpha 2.0
Login Register
» Authors » Joseph Fiore

Joseph Fiore

Explore the profile of Joseph Fiore including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 1853
Followers 0
Related Specialties
Oncology
Pharmacology
General Medicine
Top 10 Co-Authors
Mark M Awad
Amita Patnaik
Enriqueta Felip
Janis M Taube
Tudor-Eliade Ciuleanu
Mark Sausen
Lecia V Sequist
James Chih-Hsin Yang
James P Stevenson
Corey J Langer
Published In
J Thorac Oncol
Future Oncol
J Card Fail
Leuk Lymphoma
Case Rep Gastrointest Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer
Deutsch J, Wang D, Chen K, Cimino-Mathews A, Thompson E, Jedrych J, et al.
Lab Invest . 2024 Oct; 105(1):102166. PMID: 39461426
Pathologic response is an endpoint in many ongoing clinical trials for neoadjuvant regimens, including immune checkpoint blockade and chemotherapy. Whole-slide scanning of glass slides generates high-resolution digital images and allows...
2.
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis
Waser N, Quintana M, Schweikert B, Chaft J, Berry L, Adam A, et al.
JNCI Cancer Spectr . 2024 Mar; 8(3). PMID: 38521542
Background: Surrogate endpoints for overall survival in patients with resectable non-small cell lung cancer receiving neoadjuvant therapy are needed to provide earlier treatment outcome indicators and accelerate drug approval. This...
3.
Real-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer
Nadler E, Vasudevan A, Wentworth C, Robert N, Penrod J, Fiore J, et al.
Future Oncol . 2023 Sep; 19(26):1785-1800. PMID: 37665271
Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer. We examined the real-world relationship between these end  points in patients with resectable stage...
4.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer
Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M, et al.
Future Oncol . 2023 Feb; 19(8):549-557. PMID: 36815433
What Is This Summary About?: In this article, we summarize results from the ongoing phase 3 CheckMate 816 clinical study that were published in in 2022. The goal of CheckMate...
5.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Ready N, Audigier-Valette C, Goldman J, Felip E, Ciuleanu T, Campelo M, et al.
J Immunother Cancer . 2023 Feb; 11(2). PMID: 36725084
Background: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line...
6.
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study
Sengupta S, Ntambwe I, Tan K, Liang Q, Paulucci D, Castellanos E, et al.
Clin Pharmacol Ther . 2023 Jan; 113(4):867-877. PMID: 36606735
This proof-of-concept study retrospectively assessed the feasibility of applying a hybrid control arm design to a completed phase III randomized controlled trial (RCT; CheckMate-057) in advanced non-small cell lung cancer...
7.
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Merino Vega D, Nishimura K, Zariffa N, Thompson J, Hoering A, Cilento V, et al.
JCO Precis Oncol . 2022 Aug; 6:e2100372. PMID: 35952319
Purpose: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in...
8.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M, et al.
N Engl J Med . 2022 Apr; 386(21):1973-1985. PMID: 35403841
Background: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however,...
9.
Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
Fiore J, Co-van der Mee M, Maldonado A, Glasser L, Watson P
Ther Adv Vaccines Immunother . 2022 Jan; 9:25151355211057479. PMID: 35005428
An adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials...
10.
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H
Gubens M, Sequist L, Stevenson J, Powell S, Villaruz L, Gadgeel S, et al.
Lung Cancer . 2019 Mar; 130:59-66. PMID: 30885353
Objectives: Combination immunotherapy may result in improved antitumor activity compared with single-agent treatment. We report results from dose-finding and dose-expansion cohorts of the phase 1/2 KEYNOTE-021 study that evaluated combination...